Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 3/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.59 |
| ▸ | LMNA | P02545 | 2/20 | 0.57 |
| ▸ | HTT | P42858 | 2/20 | 0.57 |
| ▸ | POLB | P06746 | 2/20 | 0.54 |
| ▸ | HTR1A | P08908 | 1/20 | 0.54 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.53 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.51 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.51 |
| ▸ | CD274 | Q9NZQ7 | 5/20 | 0.50 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.50 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.49 |
| ▸ | HTR7 | P34969 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24445402 | 0.96 | CYP2D6 (0.58) | MEN1KMT2ALMNAHTTPOLB | |
| SCHEMBL19897667 | 0.88 | CD274 (0.54) | MEN1KMT2ALMNAHTTPOLB | |
| SCHEMBL19897670 | 0.88 | CD274 (0.54) | MEN1KMT2ALMNAHTTPOLB | |
| SCHEMBL30395204 | 0.88 | CD274 (0.54) | MEN1KMT2ALMNAHTTPOLB | |
| SCHEMBL24445406 | 0.87 | CYP2D6 (0.68) | MEN1KMT2AHTTHTR1AALDH1A1 | |
| SCHEMBL19916129 | 0.85 | CYP2D6 (0.66) | MEN1KMT2AHTTALDH1A1CYP2D6 | |
| SCHEMBL24445444 | 0.85 | CYP2D6 (0.66) | MEN1KMT2AHTTALDH1A1CYP2D6 | |
| SCHEMBL19939549 | 0.83 | CD274 (0.56) | MEN1KMT2AHTR1AALDH1A1CYP2D6 | |
| SCHEMBL22065486 | 0.83 | CYP2D6 (0.56) | MEN1KMT2ALMNAHTTPOLB | |
| SCHEMBL19916118 | 0.82 | CYP2D6 (0.52) | MEN1KMT2ALMNAHTTPOLB |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 13 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109863146-B | Biaryl compounds as immunomodulators | 百时美施贵宝公司 | 2023-02-28 | — | — | CN | claimed |
| EP-3507284-B1 | BIARYL COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-25 | — | — | EP | claimed |
| EP-3507284-A1 | BIARYL COMPOUNDS USEFUL AS IMMUNOMODULATORS | Bristol-Myers Squibb Company (US) | 2019-07-10 | — | — | EP | claimed |
| US-10144706-B2 | Compounds useful as immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-12-04 | — | — | US | claimed |
| WO-2018044963-A1 | BIARYL COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-08 | — | — | WO | claimed |
| US-20180057455-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-01 | — | — | US | claimed |
| EP-3507284-B1 | BIARYL COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-25 | — | — | EP | disclosed |
| EP-3507284-B1 | BIARYL COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL MYERS SQUIBB CO (US) | 2022-05-25 | — | — | EP | disclosed |
| US-10144706-B2 | Compounds useful as immunomodulators | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-12-04 | — | — | US | disclosed |
| WO-2018044963-A1 | BIARYL COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2018-03-08 | — | — | WO | disclosed |
| US-20180057455-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-01 | — | — | US | disclosed |
| US-20180057455-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-01 | — | — | US | disclosed |
| US-20180057455-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | BRISTOL-MYERS SQUIBB COMPANY | 2018-03-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10144706-B2 | Compounds useful as immunomodulators | CD74, HLA-DRB1, CD47 | MEN1 1857/4885KMT2A 4121/4885LMNA 4791/4885 |
| US-20180057455-A1 | COMPOUNDS USEFUL AS IMMUNOMODULATORS | CD74, HLA-DRB1, CD47 | MEN1 1857/4885KMT2A 4121/4885LMNA 4791/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.